Daniel Bradshaw

2.3k total citations
28 papers, 505 citations indexed

About

Daniel Bradshaw is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Daniel Bradshaw has authored 28 papers receiving a total of 505 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 12 papers in Hepatology and 8 papers in Infectious Diseases. Recurrent topics in Daniel Bradshaw's work include Hepatitis C virus research (12 papers), Hepatitis B Virus Studies (8 papers) and Liver Disease Diagnosis and Treatment (6 papers). Daniel Bradshaw is often cited by papers focused on Hepatitis C virus research (12 papers), Hepatitis B Virus Studies (8 papers) and Liver Disease Diagnosis and Treatment (6 papers). Daniel Bradshaw collaborates with scholars based in United Kingdom, Australia and United States. Daniel Bradshaw's co-authors include R.J. Arceci, Gail Matthews, Mark Danta, Krisela Steyn, Jean Fourie, Prabhjeet Phalora, Paul Klenerman, Scott M. Ward, Heike Leyendeckers and Gregory J. Dore and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Neurology.

In The Last Decade

Daniel Bradshaw

24 papers receiving 492 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Bradshaw United Kingdom 11 202 156 146 142 81 28 505
JM Kaldor Australia 16 299 1.5× 167 1.1× 284 1.9× 117 0.8× 37 0.5× 26 796
A. Molinari Italy 10 110 0.5× 187 1.2× 109 0.7× 168 1.2× 44 0.5× 17 568
Andrea Marongiu Italy 13 201 1.0× 108 0.7× 79 0.5× 29 0.2× 82 1.0× 53 591
Tomi Jun United States 14 150 0.7× 115 0.7× 150 1.0× 105 0.7× 73 0.9× 53 528
Richard D. Burt United States 13 356 1.8× 99 0.6× 195 1.3× 90 0.6× 22 0.3× 18 597
Kristina M. Brooks United States 15 183 0.9× 52 0.3× 308 2.1× 38 0.3× 87 1.1× 44 675
Xinan Wan Australia 8 123 0.6× 249 1.6× 61 0.4× 37 0.3× 53 0.7× 12 434
Warren Phipps United States 15 218 1.1× 253 1.6× 88 0.6× 26 0.2× 22 0.3× 32 460
Margaret Urban South Africa 13 269 1.3× 272 1.7× 64 0.4× 26 0.2× 65 0.8× 18 664
Xien Gui China 15 346 1.7× 50 0.3× 234 1.6× 165 1.2× 33 0.4× 33 562

Countries citing papers authored by Daniel Bradshaw

Since Specialization
Citations

This map shows the geographic impact of Daniel Bradshaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Bradshaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Bradshaw more than expected).

Fields of papers citing papers by Daniel Bradshaw

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Bradshaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Bradshaw. The network helps show where Daniel Bradshaw may publish in the future.

Co-authorship network of co-authors of Daniel Bradshaw

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Bradshaw. A scholar is included among the top collaborators of Daniel Bradshaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Bradshaw. Daniel Bradshaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Fu, Michael X., Ahmed M Elsharkawy, Brendan Healy, et al.. (2025). Occult hepatitis B virus infection: risk for a blood supply, but how about individuals’ health?. EClinicalMedicine. 81. 103095–103095.
3.
Burns, Douglas A., Jason Corwin, George R. Robinson, et al.. (2024). New York State Climate Impacts Assessment Chapter 05: Ecosystems. Annals of the New York Academy of Sciences. 1542(1). 253–340. 3 indexed citations
4.
Mbisa, Jean L., Zena Lapp, David Bibby, et al.. (2024). Identification of 2 Novel Subtypes of Hepatitis C Virus Genotype 8 and a Potential New Genotype Successfully Treated With Direct Acting Antivirals. The Journal of Infectious Diseases. 230(6). e1254–e1262. 3 indexed citations
5.
Khan, Maryam, Daniel Bradshaw, Colin Brown, et al.. (2023). Characterization of Rare Spontaneous Human Immunodeficiency Virus Viral Controllers Attending a National United Kingdom Clinical Service Using a Combination of Serology and Molecular Diagnostic Assays. Open Forum Infectious Diseases. 10(5). ofad108–ofad108. 1 indexed citations
6.
Bradshaw, Daniel, Stephen Bremner, Sumita Verma, et al.. (2023). Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease. PLoS ONE. 18(7). e0288598–e0288598. 4 indexed citations
7.
Smith, David A., Daniel Bradshaw, Jean L. Mbisa, et al.. (2021). Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy. Journal of Viral Hepatitis. 28(9). 1256–1264. 19 indexed citations
8.
Brown, Alison, Sara Croxford, Sophie Nash, et al.. (2021). COVID‐19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVID‐19 pandemic in England. HIV Medicine. 23(1). 90–102. 13 indexed citations
9.
10.
Smith, David A., Daniel Bradshaw, Jean L. Mbisa, et al.. (2020). Real-world retreatment of HCV-infected patients with prior failure to direct acting antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir. Journal of Hepatology. 73. S336–S336. 1 indexed citations
11.
Gomes, Cláudia Maria de Castro, Maria Glória Teixeira Sousa, Marliane Batista Campos, et al.. (2017). Immunopathological characterization of human cutaneous leishmaniasis lesions caused by Leishmania (Viannia) spp. in Amazonian Brazil. Parasitology Research. 116(5). 1423–1431. 8 indexed citations
12.
Bradshaw, Daniel, Jayna Raghwani, Brendan Jacka, et al.. (2016). Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men. PLoS ONE. 11(9). e0162002–e0162002. 9 indexed citations
13.
Bradshaw, Daniel, F. Lamoury, Beth Catlett, et al.. (2014). A Comparison of Seminal Hepatitis C Virus (HCV) RNA Levels During Recent and Chronic HCV Infection in HIV-Infected and HIV-Uninfected Individuals. The Journal of Infectious Diseases. 211(5). 736–743. 26 indexed citations
14.
Bradshaw, Daniel, D.J. Hughes, Λεωνιδία Λεωνίδου, et al.. (2013). Screening for HIV-related neurocognitive impairment in clinical practice: Challenges and opportunities. AIDS Care. 26(2). 160–168. 13 indexed citations
15.
Bradshaw, Daniel, Gail Matthews, & Mark Danta. (2012). Sexually transmitted hepatitis C infection. Current Opinion in Infectious Diseases. 26(1). 66–72. 82 indexed citations
16.
Ward, Scott M., Prabhjeet Phalora, Daniel Bradshaw, Heike Leyendeckers, & Paul Klenerman. (2008). Direct Ex Vivo Evaluation of Long‐Lived Protective Antiviral Memory B Cell Responses against Hepatitis B Virus. The Journal of Infectious Diseases. 198(6). 813–817. 29 indexed citations
17.
Bourne, David, et al.. (2002). Some implications of HIV / AIDS on adult mortality in South Africa.. LSHTM Research Online (London School of Hygiene and Tropical Medicine). 12(5).
18.
Dorrington, Rob, Daniel Bradshaw, Debbie Budlender, & David Bourne. (2002). The current state and future projections of the HIV/AIDS epidemic in South Africa.. PubMed. 57(11). 449–50. 9 indexed citations
19.
Bradshaw, Daniel & R.J. Arceci. (1998). Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.. Journal of Clinical Oncology. 16(11). 3674–3690. 182 indexed citations
20.
Bradshaw, Daniel, et al.. (1962). Inefficiency of Purified Diphtheria Formol Toxoid in Primary Immunization Against Diphtheria. BMJ. 2(5298). 149–151. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by JM Kaldor Breakdown of academic impact, for papers by A. Molinari Breakdown of academic impact, for papers by Andrea Marongiu Breakdown of academic impact, for papers by Tomi Jun Breakdown of academic impact, for papers by Richard D. Burt Breakdown of academic impact, for papers by Kristina M. Brooks Breakdown of academic impact, for papers by Xinan Wan Breakdown of academic impact, for papers by Warren Phipps Breakdown of academic impact, for papers by Margaret Urban Breakdown of academic impact, for papers by Xien Gui
Rankless by CCL
2026